This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
Synonyms: Pick disease, frontotemporal lobar degeneration (tau type), FTLD-Pick, Frontotemporal lobar degeneration with Pick bodies
Pick disease first appeared in clinical medicine in 1892, when the Czech neuropsychiatrist Arnold Pick (1851-1924) described a case with focal frontotemporal atrophy, language disturbance, and personality change. Pick emphasized that circumscribed cortical atrophy could be associated with clinical aphasia and personality change, but did not carry out microscopic pathology studies at the time. About 20 years later, in 1911, Alois Alzheimer discovered characteristic spherical inclusion bodies within neurons (Pick bodies) and swollen neurons (Pick cells) in a neuropathological study of a brain with frontotemporal atrophy, and named them after Pick.
Until the mid-20th century, Pick disease was grouped with Alzheimer disease as "presenile dementia," but systematic clinicopathological studies by the Lund-Manchester group in the 1980s and the 1994 publication of the Lund-Manchester diagnostic criteria established frontotemporal dementia (FTD) as an independent clinical entity. In 1998, MAPT gene variants were identified as a genetic cause of FTLD-tau, and in 2006 the TDP-43 protein was shown to be a major pathological component of FTLD, establishing the molecular pathological classification of FTLD. Currently, "Pick disease" in the narrow sense is limited to cases with Pick body pathology (FTLD-tau, 3R type) and is classified as ICD-10 G31.00. When accompanied by a dementia syndrome, a dual coding system applies in which F02.0* is additionally coded.
The core cause of Pick disease is abnormal hyperphosphorylation and intracellular accumulation of 3R tau (3-repeat tau) protein. In the normal brain, tau protein is encoded by the MAPT gene, and six isoforms (3R:4R ratio of about 1:1) are generated by alternative splicing of the pre-mRNA. In Pick disease, a MAPT splicing abnormality occurs in which 3R tau isoforms are generated overwhelmingly predominantly, so that hyperphosphorylated 3R tau detaches from microtubules and forms spherical Pick bodies in the cell body and proximal dendrites.
Sporadic Pick disease often occurs without a specific single genetic variant, and its cause is unclear. In familial cases, pathogenic missense or splicing variants of the MAPT gene (17q21.31) are the main cause. Elsewhere in the FTLD spectrum, GRN (progranulin) variants cause TDP-43 pathology, and C9orf72 repeat expansion is associated with the FTD-ALS overlap phenotype. Strictly speaking, these are genetic causes of the FTLD spectrum as a whole rather than of Pick disease (Pick body pathology). As an environmental risk factor, a history of head trauma has been suggested in some studies, but a causal relationship has not been established.
The genetic cause of Pick disease (FTLD-tau) pathology is mainly variants of the MAPT (17q21.31) gene. MAPT variants are identified in about 15-25% of FTLD-tau cases, and more than 300 pathogenic variants, including P301L, R406W, V337M, G272V, and N279K, have been reported. MAPT variants show an autosomal dominant inheritance pattern with nearly complete penetrance. Age of onset varies from the 30s to the 70s depending on the type of variant. The H1/H2 haplotype around the MAPT gene is also related to the risk of sporadic FTLD-tau, and H1 haplotype homozygosity increases the risk of Pick disease and PSP.
Across the FTLD spectrum, GRN variants (FTLD-TDP type A), C9orf72 repeat expansion (FTLD-TDP type B), TARDBP, and FUS are also causes of familial FTD. When a GRN variant is identified, plasma progranulin concentration (reduced to 30-50% of normal) is a diagnostic clue. In patients with a family history, an FTD gene panel (including MAPT, GRN, C9orf72, TARDBP, FUS, VCP, CHMP2B, and TBK1) is recommended. Genetic counseling must be provided to family members with confirmed positive results before predictive testing.
The prevalence and incidence of the frontotemporal lobar degeneration (FTLD) spectrum, including Pick disease, are lower than those of Alzheimer disease, but it is one of the major causes of early-onset dementia under age 65. In European and North American studies, the prevalence of FTD is reported at about 15-22 per 100,000 in the population aged 45-64 and about 3-9 per 100,000 in those aged 65 and over. The incidence is estimated at about 2.7-4.1 per 100,000 per year. Data in Korea are limited, but the number of prevalent cases is increasing with greater diagnostic awareness of FTD and population aging.
Pathologically confirmed Pick disease (FTLD-tau, Pick body pathology) accounts for about 20-30% of all FTD, with FTLD-TDP (about 40-50%) the most common. The median age of onset is 58-65 years, and there is a tendency to be slightly higher in men than women, but most studies find no statistically significant sex difference. Familial FTD accounts for about 30-40% of the total, of which MAPT variants, GRN variants, and C9orf72 repeat expansion are the main causes. Because accompanying movement disorders (parkinsonian syndrome, PSP, CBD, ALS) occur in a considerable proportion, evaluating FTLD with purely neuropsychological symptoms alone is insufficient.
The molecular pathophysiology of Pick disease can be summarized as 3R tau overproduction due to MAPT pre-mRNA splicing abnormality, with its abnormal hyperphosphorylation and formation of insoluble aggregates. Whether exon 10 of the MAPT gene is included or excluded determines the 4-repeat (4R) or 3-repeat (3R) tau isoform, and in Pick disease the proportion of the 3R isoform is extremely increased. 3R tau has lower microtubule-binding affinity than 4R tau, so it detaches easily and has a strong tendency to form beta-sheet structures in the cytoplasm.
Hyperphosphorylated 3R tau accumulates in the cell body and proximal dendrites to form spherical Pick bodies, which are identified by Gallyas silver staining and a 3R-selective tau antibody (RD3). Pick cells (ballooned neurons) show swelling of the cell body and loss of Nissl substance and are positive for phosphorylated tau and alpha-B-crystallin. Neurons in layers 3-5 of the frontotemporal cortex are selectively affected, and in particular the orbitofrontal cortex, anterior cingulate cortex, anterior insula, and anterior temporal cortex, which are responsible for language and social cognition, are damaged early.
Prion-like propagation of tau oligomers is drawing attention as a model explaining the network spread of lesions. Microglia-mediated neuroinflammation also contributes to lesion progression, and when tau phagocytosis through the TREM2 receptor is impaired, tau clearance decreases. Synapse loss occurs before neuronal cell death and serves as an early mechanism of cognitive and behavioral decline, and abnormal excitatory glutamatergic neurotransmission and imbalance of inhibitory GABA signaling are associated with clinical symptoms.
Pick disease (G31.00) usually presents clinically as behavioral variant frontotemporal dementia (bvFTD), with personality and behavioral changes reflecting frontal lobe dysfunction appearing before cognitive decline. Characteristic early symptoms are disinhibition (socially inappropriate remarks and behavior, sexually inappropriate behavior, impulsive acts), apathy (decreased motivation, spontaneity, and emotional responsiveness), loss of empathy, compulsive and repetitive behavior (stereotypy), changes in eating habits (preference for sweet foods, overeating, preoccupation with food), and oral behaviors.
Language symptoms include reduced speech output, stereotyped utterances, echolalia, perseveration, and decreased verbal fluency, and may progress to mutism. On the other hand, orientation and episodic memory tend to be relatively preserved early on, which is an important clinical feature distinguishing it from Alzheimer disease. Executive function, working memory, decision-making ability, abstract thinking, and cognitive flexibility are selectively impaired.
In some cases, language variant FTD (primary progressive aphasia, PPA) and semantic variant FTD (semantic variant PPA) may appear, mainly reflecting temporal lobe involvement. Motor symptoms resembling parkinsonian syndrome, corticobasal syndrome (CBS), or progressive supranuclear palsy (PSP) may also accompany, varying with the underlying neuropathology type and site of neural injury. In FTD-ALS overlap cases, upper and lower motor neuron signs are added.
On neurological examination, there is often no clear focal neurological deficit early on, but primitive reflexes reflecting frontal lobe dysfunction (grasp reflex, glabellar reflex, sucking reflex) may appear early. Imitation behavior: automatically copying the examiner's actions, and utilization behavior: automatically using objects in front of the patient appropriately or inappropriately, may be found as signs of damage to the supplementary motor area and frontal lobe. Insight is severely reduced, and it is characteristic that the patients themselves do not recognize behavioral abnormalities or impaired judgment.
On neuropsychological testing, marked decline is found on frontal function tests such as the Frontal Assessment Battery (FAB), Trail Making Test B, verbal fluency (letter fluency and semantic fluency), and the Wisconsin Card Sorting Test (WCST), whereas the decline in delayed recall, the main indicator of Alzheimer disease, may be mild early on. Behavioral observation reveals hyperactivity, distractibility, impulsivity, perseverative testing, and easy distraction.
On imaging, in addition to frontotemporal atrophy on brain MRI, damage to frontal white matter tracts is found on diffusion tensor imaging (DTI). When motor symptoms accompany, parkinsonian syndrome (rigidity, bradykinesia, postural instability), oculomotor disorders, and apraxia may be found on examination.
Tools specific to frontal function are essential for clinical screening of Pick disease. The Frontal Assessment Battery (FAB) is an 18-point scale consisting of 6 items (conceptualization, mental flexibility, motor programming, sensitivity to interference, inhibitory control, environmental autonomy), and a total score of 12 or less suggests frontal lobe dysfunction. The MMSE does not adequately reflect frontal symptoms and is unsuitable as a stand-alone screen, and the MoCA includes frontal-executive function items but may miss early bvFTD.
For screening of behavioral symptoms, the disinhibition, apathy, and aberrant behavior items of the Neuropsychiatric Inventory (NPI) are used, and FTD-specific tools, the Cambridge Behavioural Inventory-Revised (CBI-R), Frontal Systems Behaviour Scale (FrSBe), and Functional Rating Scale for Symptoms of Dementia (FRSSD), are used in caregiver-report format. The FTDC (behavioral variant FTD criteria, 2011) checklist of the 6 core features is used as a screening and diagnostic guide. Brain MRI (presence of frontotemporal atrophy), FDG-PET (frontotemporal hypometabolism), and amyloid PET (a negative result supports exclusion of Alzheimer disease) are used as adjunctive screening imaging tests.
In blood tests, plasma progranulin measurement is performed when a GRN variant is suspected, and an FTD gene panel including C9orf72 repeat testing is performed in stages when there is a family history or suspected ALS overlap. Elevated plasma NfL (neurofilament light chain) suggests ongoing neurodegeneration, and higher levels have been reported in FTD than in Alzheimer disease.
The clinical diagnosis of Pick disease (G31.00) uses the behavioral variant FTD (bvFTD) diagnostic criteria according to the 2011 international FTDC criteria (Rascovsky et al.). Possible bvFTD is defined as clinical evidence of a neurodegenerative disease + 3 or more of the 6 core features, probable bvFTD as the possible criteria + frontal/anterior temporal atrophy, hypometabolism, or hypoperfusion on imaging, and definite bvFTD as confirmation by histopathology or a known pathogenic variant.
In histopathologic confirmation, Pick disease (FTLD-tau, Pick type) must meet the findings of ① spherical intraneuronal inclusions (Pick bodies) positive on Gallyas silver staining and tau immunohistochemistry (AT8, PHF-1), ② ballooned neurons (Pick cells), ③ strong positivity for the 3R-selective tau antibody (RD3), and ④ negative or weak reaction to 4R tau (RD4 antibody). In contrast, PSP is characterized by predominant 4R tau and CBD by astrocytic and oligodendrocytic tau pathology (astrocytic plaques, coiled bodies), so they are distinguished pathologically.
Tau PET (18F-flortaucipir) shows high binding to the mixed 3R/4R tau of Alzheimer disease, but binding to the 3R tau of Pick disease is limited, so only negative or weak binding may appear. This suggests that a positive tau PET does not mean exclusion of Pick disease, and next-generation tau PET tracers (18F-PI-2620, 18F-MK-6240) are under study for detecting FTLD-tau. In CSF biomarkers, Pick disease is distinguished from Alzheimer disease by normal Aβ42 and normal or mildly elevated p-tau181, and elevated plasma NfL and GFAP are found.
There is currently no approved disease-modifying treatment for Pick disease (G31.00), and treatment consists entirely of symptomatic therapy aimed at symptom relief and maintenance of function. Cholinesterase inhibitors (AChEI) have no evidence in FTD or may have adverse effects reported, so they are not recommended in pure Pick disease/bvFTD. A randomized controlled trial of memantine in bvFTD also failed to demonstrate a significant effect.
For control of behavioral symptoms, SSRIs (sertraline, fluvoxamine, paroxetine) have been reported to be beneficial for disinhibition, compulsive behavior, and overeating in some clinical trials and observational studies. Low-dose atypical antipsychotics (quetiapine) are used for severe disinhibition, aggression, and agitation, but the risk of worsening parkinsonian syndrome must be considered. For sleep disturbance, small studies have reported that trazodone is effective in improving nighttime insomnia and nighttime behavioral symptoms without causing somnolence.
Non-pharmacologic treatment includes structured daily routines, behavioral therapy, environmental modification (restricting access to food, safety devices), speech therapy (including AAC), occupational therapy, and physical therapy. Family education and psychological support are essential for preventing caregiver burnout. As research on disease-modifying treatment, anti-tau immunotherapy (zagotenemab, semorinemab), a tau aggregation inhibitor (TRx0237), and progranulin replacement therapy for GRN variant carriers (ILB-202) are in clinical trials.
Pick disease is an irreversible progressive neurodegenerative disease, with a median survival from clinical diagnosis to death of about 6-9 years. The total duration from symptom onset to death varies greatly among individuals, from 2 to 20 years. MAPT variant carriers and FTD-ALS overlap cases with C9orf72 repeat expansion show rapid progression. In FTD-ALS overlap, respiratory failure becomes the main cause of death and the prognosis is even worse, with an average survival of about 3-5 years from onset reported.
Clinical progression is divided into an early stage of personality and behavioral abnormality, a middle stage of global cognitive decline and loss of language, and a late stage of akinetic mutism and complete dependence. The CDR plus NACC FTLD sum of boxes score, the Frontotemporal Dementia Rating Scale (FRS), and the Clinical Global Impression are used to track functional level. Higher baseline plasma NfL is associated with faster cognitive and functional decline, and its role as a prognostic biomarker is being validated.
Advance care planning should begin early in diagnosis, while the patient can still express their wishes, and requires proactive support from the multidisciplinary team for preparing a life-sustaining treatment plan, designating a guardian, financial management planning, and linkage to end-of-life hospice care.
There is currently no established primary prevention for Pick disease. For familial FTD-tau (MAPT variants), after the causative variant is identified in the index patient, genetic counseling and predictive testing can be offered to adult family members, but this must be done with accompanying counseling by a psychological specialist. Prospective cohort studies including the GENFI (Genetic FTD Initiative) are exploring prodromal-stage biomarkers, and foundational research is under way for the possibility of preemptive treatment before symptom onset.
Preventive intervention clinical trials of progranulin replacement therapy in GRN variant carriers are under way, and preventive antisense oligonucleotide (ASO) treatment studies are also being planned in C9orf72 carrier cohorts. For general brain health maintenance, management of cardiovascular risk factors, prevention of head trauma, regular exercise, and increased social participation are recommended for preventing all forms of neurodegeneration, including FTD. Linkage to the community dementia support center (Chimae Ansim Center) for caregivers and families, psychological support, and guidance on legal and financial advance preparation are core roles of the multidisciplinary team from immediately after diagnosis.